BEACON (2013) — Trial Summary

BEACON (2013): The trial evaluating bardoxolone methyl in patients with type 2 diabetes and stage 4 CKD was terminated early due to an increased risk of heart failure and cardiovascular events, despite improvements in eGFR.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.